PMID- 32608059
OWN - NLM
STAT- MEDLINE
DCOM- 20210827
LR  - 20210827
IS  - 2574-173X (Electronic)
IS  - 2574-173X (Linking)
VI  - 40
IP  - 3
DP  - 2020 Sep
TI  - Differential sensitivity to detect prosocial effects of 
      3,4-methylenedioxymethamphetamine (MDMA) in different social approach paradigms 
      in mice.
PG  - 297-301
LID - 10.1002/npr2.12124 [doi]
AB  - A recreational drug, 3,4-methylenedioxymethamphetamine (MDMA), has prosocial 
      effects including increased sociability, enhancement of trust feelings, and 
      empathy. Although several methods, such as the social interaction and three 
      chamber tests, have been used, the neural mechanisms underlying the prosocial 
      effects have not been well understood. In the present study, based on a social 
      approach paradigm using a single-chamber apparatus, we have developed two 
      reproducible and simple social approach tests, SAT1 and SAT2, in ICR mice. In the 
      SAT1, an unfamiliar mouse was set in a wire mesh cylinder cage that was placed in 
      the center of a rectangular open field, while in the SAT2, an unfamiliar mouse 
      was set in a wire mesh rectangular cage that was placed along a wall of a 
      rectangular open field. Although MDMA treatment enhanced sociability in both SAT1 
      and SAT2, the ratio of high sociability mice was higher in the SAT2 than in the 
      SAT1, indicating a differential sensitivity to detect the prosocial effects. 
      Thus, we suggest that the SAT2 is a promising and suitable method to explore the 
      neuronal mechanisms underlying the effects of MDMA.
CI  - (c) 2020 The Authors. Neuropsychopharmacology Reports published by John Wiley & 
      Sons Australia, Ltd on behalf of The Japanese Society of Neuropsycho 
      Pharmacology.
FAU - Mukai, Satoko
AU  - Mukai S
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, Japan.
FAU - Nakada, Sao
AU  - Nakada S
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, Japan.
FAU - Kamada, Hikari
AU  - Kamada H
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, Japan.
FAU - Yaguchi, Ryuma
AU  - Yaguchi R
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, Japan.
FAU - Deyama, Satoshi
AU  - Deyama S
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, Japan.
FAU - Kaneda, Katsuyuki
AU  - Kaneda K
AUID- ORCID: 0000-0001-7046-9275
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200630
PL  - United States
TA  - Neuropsychopharmacol Rep
JT  - Neuropsychopharmacology reports
JID - 101719700
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - *Altruism
MH  - Animals
MH  - Hallucinogens/*pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Social Behavior
MH  - Social Interaction/*drug effects
PMC - PMC7722663
OTO - NOTNLM
OT  - MDMA
OT  - drug abuse
OT  - mouse
OT  - prosocial effect
OT  - social approach
COIS- The authors declare no conflict of interest.
EDAT- 2020/07/02 06:00
MHDA- 2021/08/28 06:00
PMCR- 2020/06/30
CRDT- 2020/07/02 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/05/29 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/08/28 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/06/30 00:00 [pmc-release]
AID - NPR212124 [pii]
AID - 10.1002/npr2.12124 [doi]
PST - ppublish
SO  - Neuropsychopharmacol Rep. 2020 Sep;40(3):297-301. doi: 10.1002/npr2.12124. Epub 
      2020 Jun 30.